| Name | Title | Contact Details |
|---|---|---|
Brett Silton |
Head of Corporate Compliance | Profile |
Donna Shiroma |
General Counsel | Profile |
Neometrics Inc is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Eastern States Eyewear is a Elmont, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Futuremed America Inc is a Granada Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
iHealth is dedicated to helping people lead healthier lives. Our goal is to make it as easy as possible for individuals of all ages to take a more active role in managing their health. We do this by designing and manufacturing innovative, consumer-friendly, mobile personal healthcare products that connect to the cloud. Our products are easy-to-use, making it simple for consumers to accurately measure, track and share a full range of health vitals. By automatically connecting the data through the cloud, consumers are able to see a more comprehensive view of their vitals and easily share information with healthcare professionals or loved ones. Our award-winning line of products include blood pressure monitors, blood glucose monitors, body analysis scales, pulse oximeters and activity and sleep trackers. All of our products sync directly with a free mobile app that makes monitoring, viewing, storing and sharing of health vitals simple and comprehensive.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.